MA32928B1 - Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer - Google Patents

Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer

Info

Publication number
MA32928B1
MA32928B1 MA33784A MA33784A MA32928B1 MA 32928 B1 MA32928 B1 MA 32928B1 MA 33784 A MA33784 A MA 33784A MA 33784 A MA33784 A MA 33784A MA 32928 B1 MA32928 B1 MA 32928B1
Authority
MA
Morocco
Prior art keywords
cxcr4
cancer
treatment
antibodies
cxcr4 antibodies
Prior art date
Application number
MA33784A
Other languages
Arabic (ar)
English (en)
Inventor
Christine Klinguer-Hamour
Véronique Grenier-Caussanel
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32928B1 publication Critical patent/MA32928B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN NOUVEL ANTICORPS ISOLÉ, OU LES COMPOSÉS DÉRIVÉS OU DES FRAGMENTS FONCTIONNELS DE CELUI-CI, CAPABLES DE SE LIER À CXCR4 MAIS ÉGALEMENT D'INDUIRE DES CHANGEMENTS DE CONFORMATION DES HOMODIMÈRES ET/OU HÉTÉRODIMÈRES DE CXCR4. PLUS PARTICULIÈREMENT, LA PRÉSENTE INVENTION CONCERNE LES ANTICORPS 414H5 ET 515H7, SPÉCIFIQUES DE LA PROTÉINE CXCR4, AINSI QUE LEUR UTILISATION POUR LE TRAITEMENT DU CANCER. LA PRÉSENTE INVENTION CONCERNE EN OUTRE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT DE TELS ANTICORPS ET UN PROCÉDÉ POUR LA SÉLECTION DE TELS ANTICORPS.
MA33784A 2008-10-01 2009-10-01 Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer MA32928B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (fr) 2008-10-01 2008-10-01 Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer
US17374309P 2009-04-29 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (fr) 2008-10-01 2009-10-01 Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA32928B1 true MA32928B1 (fr) 2012-01-02

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33784A MA32928B1 (fr) 2008-10-01 2009-10-01 Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer

Country Status (28)

Country Link
US (4) US8557964B2 (fr)
EP (2) EP2172485A1 (fr)
JP (1) JP5723279B2 (fr)
KR (1) KR101671039B1 (fr)
CN (1) CN102209730B (fr)
AR (1) AR073748A1 (fr)
AU (1) AU2009299787B2 (fr)
BR (1) BRPI0920531A2 (fr)
CA (1) CA2738782C (fr)
CL (1) CL2011000730A1 (fr)
CY (1) CY1115572T1 (fr)
DK (1) DK2342233T3 (fr)
ES (1) ES2503732T3 (fr)
GE (1) GEP20146084B (fr)
HR (1) HRP20140899T1 (fr)
IL (1) IL212066A (fr)
MA (1) MA32928B1 (fr)
MX (1) MX2011003509A (fr)
NZ (1) NZ592363A (fr)
PL (1) PL2342233T3 (fr)
PT (1) PT2342233E (fr)
RS (1) RS53578B1 (fr)
RU (1) RU2573897C2 (fr)
SI (1) SI2342233T1 (fr)
TW (1) TWI469792B (fr)
UA (1) UA102867C2 (fr)
WO (1) WO2010037831A1 (fr)
ZA (1) ZA201102969B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (fr) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anticorps anti CXCR4 pour le traitement du VIH
EP2371863A1 (fr) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Anticorps humanisé anti CXCR4 pour le traitement du cancer
CN103180342A (zh) * 2010-10-27 2013-06-26 皮埃尔法布雷医药公司 用于治疗hiv的抗体
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP3626739A1 (fr) 2011-06-24 2020-03-25 Stephen D. Gillies Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
SG11201600171SA (en) * 2013-08-02 2016-02-26 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
CN105593362B (zh) 2013-09-23 2021-09-10 威尔逊沃夫制造公司 遗传修饰动物细胞的改进方法
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
BR112017026189A2 (pt) 2015-06-12 2018-08-14 Bristol Myers Squibb Co tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
EP3374381A4 (fr) 2015-11-09 2019-05-15 The University Of British Columbia Épitopes dans la région centrale de la bêta-amyloïde et anticorps conformationnels sélectifs associés
WO2017079835A1 (fr) * 2015-11-09 2017-05-18 The University Of British Columbia Épitopes de la bêta-amyloïde et anticorps associés
EP3408378B1 (fr) 2016-01-25 2022-01-12 NantCell, Inc. Cellules nk présentant une signalisation cxcl12/cxcr4 modifiée
JPWO2017203799A1 (ja) * 2016-05-25 2019-02-28 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20190389958A1 (en) * 2017-01-31 2019-12-26 Msm Protein Technologies, Inc. Anti-cxcr4 antibodies
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019175802A1 (fr) 2018-03-13 2019-09-19 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz Anticorps anti-cxcr4 combiné à des cellules tueuses naturelles activées et développées pour une immunothérapie anticancéreuse
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
WO2022133169A1 (fr) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Systèmes récepteurs antigéniques chimériques ayant une spécificité de récepteur adaptable
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
WO2025049591A1 (fr) * 2023-08-28 2025-03-06 Regeneron Pharmaceuticals, Inc. Anticorps anti-cxcr4 et leurs utilisations
CN118255888A (zh) * 2023-08-31 2024-06-28 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2006086883A1 (fr) * 2005-02-16 2006-08-24 Universite De Montreal Biocapteurs permettant de surveiller l'activation de la proteine g induite par un recepteur
WO2006089141A2 (fr) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Anticorps contre cxcr4 et leurs procédés d'utilisation
CN102027015A (zh) * 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体

Also Published As

Publication number Publication date
ZA201102969B (en) 2011-12-28
CN102209730A (zh) 2011-10-05
US8557964B2 (en) 2013-10-15
RU2573897C2 (ru) 2016-01-27
TWI469792B (zh) 2015-01-21
TW201018483A (en) 2010-05-16
EP2342233A1 (fr) 2011-07-13
HK1163119A1 (en) 2012-09-07
PT2342233E (pt) 2014-10-03
AU2009299787B2 (en) 2015-06-18
ES2503732T3 (es) 2014-10-07
CA2738782A1 (fr) 2010-04-08
WO2010037831A1 (fr) 2010-04-08
US20110287451A1 (en) 2011-11-24
UA102867C2 (uk) 2013-08-27
KR20110081229A (ko) 2011-07-13
JP5723279B2 (ja) 2015-05-27
NZ592363A (en) 2012-08-31
AU2009299787A1 (en) 2010-04-08
IL212066A (en) 2015-05-31
CA2738782C (fr) 2017-11-28
DK2342233T3 (da) 2014-09-29
EP2172485A1 (fr) 2010-04-07
CY1115572T1 (el) 2017-01-04
US20110020218A1 (en) 2011-01-27
AR073748A1 (es) 2010-12-01
US20110294156A1 (en) 2011-12-01
CN102209730B (zh) 2014-11-05
BRPI0920531A2 (pt) 2021-02-23
RU2011115559A (ru) 2012-11-10
EP2342233B1 (fr) 2014-06-25
US9388248B2 (en) 2016-07-12
JP2012504401A (ja) 2012-02-23
CL2011000730A1 (es) 2012-02-03
GEP20146084B (en) 2014-05-13
US20140050661A1 (en) 2014-02-20
AU2009299787A2 (en) 2011-06-02
MX2011003509A (es) 2011-05-02
KR101671039B1 (ko) 2016-11-01
SI2342233T1 (sl) 2014-10-30
RS53578B1 (sr) 2015-02-27
PL2342233T3 (pl) 2014-11-28
HRP20140899T1 (hr) 2014-11-07
IL212066A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
BR0211953A (pt) Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
MA30337B1 (fr) Anticorps
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA30891B1 (fr) Nouveaux anticorps anti-proliferation
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA28982B1 (fr) Anticorps antagonistes de il-17
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
EP1796669A4 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MA30384B1 (fr) Therapies combinatoires